- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05040906
A Study Comparing the Efficacy and Safety Between H-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients
A Phase 3, Randomized, Double-blind Study of H02 Plus CHOP Versus R-CHOP in Patients With Diffuse Large B-cell Lymphoma
This trial is a Multicenter, randomized, double-blind, parallel, controlled, and equivalence phase Ⅲ study.
Primary objective:
The purpose is to compare the objective response rate of H02 (rituximab biosimilar) plus CHOP and rituximab plus CHOP, as first-line treatment of diffuse large B-cell lymphoma.
Secondary objective:
The purpose is to compare the safety of H02 combined with CHOP regimen and rituximab injection (Rituximab®) combined with CHOP regimen in the treatment of newly treated diffuse large B-cell lymphoma.
Study Overview
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: jianfeng zhou, Doctor
- Phone Number: 13627284963
- Email: jfzhoutj@163.com
Study Locations
-
-
Shandong
-
Linyi, Shandong, China, 276006
- Recruiting
- Shandong New Time Pharmaceutical Co., LTD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Untreated CD20-positive DLBCL confirmed.
- 18 years to 75 years; Male or female patients.
- IPI score of 1 to 2 and an ECOG performance status of 0 to 2.
- More than 6 months life expectancy.
- At least one measurable lymph node:
- For intranodal lesions, equal or greater than 1.5 cm in the long axis and equal or greater than 1.0 cm in the short diameter; For extranodal lesions, equal or greater than 1.0 cm in the long axis.
- Adequate cardiac function (LVEF≥50%).
- Absolute neutrophil count(ANC) ≥1.5*109/L and platelet count(PLT) ≥75*109/L and hemoglobin ≥75g/L, total bilirubin level ≤1.5×upper limit of normal (ULN), aspartic acid Aminotransferase (AST), alanine aminotransferase (ALT)≤2.5×ULN, creatinine level (Cr)≤1.5×ULN.
- Signed an informed consent form which was approved by the institutional review board of the respective medical center.
Exclusion Criteria
- Primary central nervous system(CNS) lymphoma, secondary CNS involvement, primary skin DLBCL (leg type), primary mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, and primary exudation Lymphoma, T-cell/histiocytosis-rich large B-cell lymphoma, ALK-positive large B-cell lymphoma, plasmablastic lymphoma, lymphoma-like granuloma, EBV-positive mucosal skin ulcer, HHV8+DLBCL, NOS, primary testicular lymphomas.
- High-grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangement diagnosed by fluorescence in situ hybridization (FISH).
- B-cell lymphoma has characteristics between DLBCL and classic HL, and cannot be divided into types.
- Transformed lymphoma. those who have transformed from other types of lymphomas, such as follicular lymphoma, marginal zone B-cell lymphoma, and chronic lymphocytic leukemia/small B-cell lymphoma.
- History of other malignancy, except for skin basal cell carcinoma and cervical carcinoma in situ and has been in remission without treatment for >/= 5 years prior to enrolment.
- Severe mental illness.
- Positive for HIV infection.
- Positive for HCV infection.
- Patients who have HBV (+) are eligible.
- History of anti-CD20 monoclonal antibody treatment for other disease (e.g., rheumatoid arthritis).
- Previous treatment for NHL, including chemotherapy, immunotherapy, radiotherapy, monoclonal antibody therapy or surgical treatment (except lymph node biopsies diagnostic surgery and biopsy).
- Participation in another clinical trial in the past 3 months.
- Vaccination with a attenuated live vaccine within 4 weeks.
- Use of hemopoietic cytokine in the past 2 weeks, e.g. granulocyte colony stimulating factor(G-CSF).
- Disease or symptom by the investigator's discretion(interstitial pneumonia, Uncontrollable systemic infections,severe cardiovascular disease (New York Heart Association functional class III or IV, myocardial infarction or unstable arrhythmia or unstable angina in the last 6 months, severe cardiac insufficiency, rogressive multifocal leukoencephalopathy), uncontrolled hypertension (SBP≥180mmHg and/or DBP≥100mmHg), active autoimmune diseases)
- Known hypersensitivity to any of the study drugs or its ingredients.
- Prior treatment with anthracycline.
- DLBCL invaded by special parts such as testis, breast, ovary, etc.
- Pregnant or lactating women.
- The researcher believes that it is not suitable for enrollment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: H02+ Chemotherapy
Participants received six cycles of H02(375 mg/m2) combined with six cycles of standard cyclophosphamide,doxorubicin,vincristine,and prednisone/prednisolone(CHOP) chemotherapy(21-day cycles).
|
Drug:H02 375 mg/m2,administered intravenously(IV) on Day1 of each 21-day cycle for 6 cycles. Drug : Cyclophosphamide 750 mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle. Drug:Doxorubicin 50 mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle. Drug :Vincristine 1.4mg mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle. Drug: Prednisone 100 mg administered orally on Days 2-6 of each 21-day cycle. |
Active Comparator: Rituxan+Chemotherapy
Participants received six cycles of Rituxan combined with six cycles of standard cyclophosphamide,doxorubicin,vincristine,and prednisone(CHOP) chemotherapy(21-day cycles).
|
Drug: Rituxan 375 mg/m2,administered intravenously(IV) on Day1 of each 21-day cycle for 6 cycles. Drug : Cyclophosphamide 750 mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle. Drug: Doxorubicin 50 mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle. Drug : Vincristine 1.4mg mg/m2,administered intravenously(IV) on Day 2 of each 21-day cycle. Drug: Prednisone 100 mg administered orally on Days 2-6 of each 21-day cycle. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ORR(based on the evaluation of the IRC)
Time Frame: 18 weeks
|
To evaluate the objective response rate (ORR) in patients with previously untreated Diffuse Large B-cell Lymphoma after six periods of treatment.
|
18 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ORR(based on the judgment of the investigator)
Time Frame: 18 weeks
|
18 weeks
|
|
Complete response (CR) rate (based on the evaluation of the IRC and investigator)
Time Frame: 18 weeks
|
CR was defined as the complete disappearance of all previously detectable disease signs.
CR rate was percentage of participants with a CR event.
|
18 weeks
|
1-year progression-free survival (PFS) rate
Time Frame: 1 year
|
PFS was defined as the time from randomization to first occurrence of disease progression, relapse, or death from any cause.
The proportion of subjects without disease progression or death from any cause after randomization for one year.
|
1 year
|
Duration of remission within 1 year (DOR)
Time Frame: 1 year
|
The time from the first assessment of complete response or partial response to the first assessment of PD or death after randomization within 1 year.
|
1 year
|
1-year overall survival (OS) rate
Time Frame: 1 year
|
The proportion of subjects who did not die from any cause after randomization for 1 year.
|
1 year
|
1-year event-free survival (EFS) rate
Time Frame: 1 year
|
OS was defined as the time from randomization to death from any cause.
Percentage of subjects without disease progression, death, or any interruption of treatment at 1 year of randomization
|
1 year
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
- Physiological Effects of Drugs
- Antirheumatic Agents
- Antineoplastic Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Rituximab
Other Study ID Numbers
- NTP-H02-Ⅰ-Ⅲ
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recruiting
-
Samsung Medical CenterCompletedRecruiting | CompletedKorea, Republic of
-
Shengjing HospitalRecruiting
-
The First Affiliated Hospital of Soochow UniversityNorthern Jiangsu Province People's Hospital; The Second People's Hospital of... and other collaboratorsRecruitingRecruiting | T-cell Acute Lymphoblastic LeukemiaChina
-
Tocagen Inc.TerminatedMelanoma | Sarcoma | Lymphoma | Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Bladder Cancer | Triple Negative Breast Cancer | IDH1 Mutated Solid Tumors | IDH1 Mutated or MGMT Methylated Recurrent HGG (Not Recruiting)United States
Clinical Trials on H02+CHOP
-
UNEEG Medical A/SWithdrawn
-
UNEEG Medical A/STerminated
-
Japan Clinical Oncology GroupMinistry of Health, Labour and Welfare, JapanTerminatedNon-Hodgkin's LymphomaJapan
-
Yune ZhaoUnknownHard Nuclear Cataract | Corneal Endothelial Cell | Progressive Cracking TechniqueChina
-
Emergent BioSolutionsTerminated
-
Sherief Abd-ElsalamRecruiting
-
Ruijin HospitalActive, not recruitingPeripheral T-cell LymphomaChina
-
Sun Yat-sen UniversityCompletedDiffuse Large B-cell Lymphoma
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingPeripheral T-cell Lymphoma
-
Nanjing Yoko Biomedical Co., Ltd.RecruitingDiffuse Large B-Cell Lymphoma, Unspecified SiteChina